相关实验视频
Updated: Jul 13, 2025

11:51
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
12.0K
合成和优化1-替代的伊米达佐[4,5-c]林TLR7激动剂的合成和优化
Emma G DeYoung1, Justin M Howe1, Siteng Fang1
1Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, New York 13790, United States.
ACS medicinal chemistry letters
|October 18, 2023
概括
研究人员开发了新型的托尔类受体7 (TLR7) 激动剂,用于抗体药物合物 (ADC) 疗法,其强度提高. 疏水性乙尾改善了TLR7激动剂的活性,从而产生了强大的抗癌剂.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 托尔类受体7 (TLR7) 激动剂在治疗癌症和自身免疫性疾病方面表现有前途.
- 之前的研究发现了一种强大的TLR7选择性激动剂 (化合物1),适用于抗体-药物合物 (ADC) 输送.
- 下一代ADC疗法需要具有更强效和优化特性的TLR7激动剂.
研究的目的:
- 进行合成化学和结构-活性关系 (SAR) 研究.
- 为下一代ADC应用开发具有增强功能的新型TLR7激动剂.
- 调查结构修改对TLR7激动剂活性,选择性和透性的影响.
主要方法:
- 基于母化合物的新型TLR7激动剂类型的合成 1.
- 结构-活性关系 (SAR) 研究涉及水酸尾巴和酸尾巴的修饰.
- 对TLR7激动剂活性,TLR8选择性和细胞透性的评估.
- 分子建模以阐明结构-活动关系.
主要成果:
- 在化合物1中添加疏水性乙尾部,通常保持或改善TLR7激动剂活性.
- 这些修改并没有影响TLR8.8的细胞透性或选择性.
- 相比之下,简单的尾添加导致功效显著下降.
- 化合物17b,16b和16d被确定为非常强大的TLR7激动剂.
- 这些强烈的激动剂在低纳米分子度下诱导了小鼠巨细胞和人类外周血液单核细胞 (hPBMCs) 的激活.
结论:
- 疏水性乙尾的修改是增强TLR7对ADC发展的agonist功能的可行策略.
- 化合物17b,16b和16d是下一代针对癌症的ADC治疗的有希望的候选者.
- 分子建模为观察到的强度差异的结构基础提供了洞察力.
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
589
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
589
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.1K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K

